0001209191-24-001770.txt : 20240117 0001209191-24-001770.hdr.sgml : 20240117 20240117170332 ACCESSION NUMBER: 0001209191-24-001770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240112 FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Readnour Robin Shane CENTRAL INDEX KEY: 0001914883 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 24539201 MAIL ADDRESS: STREET 1: 3835 CLEGHORN AVENUE, SUITE 300 CITY: NASHVILLE STATE: TN ZIP: 37215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-12 0 0001880438 AN2 Therapeutics, Inc. ANTX 0001914883 Readnour Robin Shane C/O AN2 THERAPEUTICS, INC. 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 1 0 0 0 1 Common Stock 2024-01-12 4 S 0 706 21.92 D 414788 I See footnotes Common Stock 2024-01-12 4 S 0 719 21.91 D 485073 I See footnotes The reported sale of 706 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on August 30, 2023. This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.96. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities. Shares held directly by MGC 2018 LP. The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023. This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Shares held directly by MGC 2018 QP. /s/ Jay Ferguson, Attorney-in-Fact for Robin Shane Readnour 2024-01-17